Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic.
Weizmann Institute of Science, Rehovot, Israel.
FEBS J. 2019 Oct;286(19):3858-3873. doi: 10.1111/febs.14945. Epub 2019 Jun 12.
Interleukin 24 (IL-24) is a cytokine with the potential to be an effective treatment for autoimmune diseases and cancer. However, its instability and difficulties in its production have hampered detailed biological and biophysical studies. We approached the challenges of IL-24 production by using the PROSS algorithm to design more stable variants of IL-24. We used homology models built from the sequences and known structures of IL-20 and IL-19 and predicted and produced several extensively mutated IL-24 variants that were highly stable and produced in large yields; one of them was crystallized (IL-24B, PDB ID 6GG1; 3D Interactive at http://proteopedia.org/w/Journal: FEBS_Journal:1). The mutated variants, however, lost most of their binding capacity to the extracellular parts of cognate receptors. While the affinity to the receptor 2 (IL-20R2) was preserved, the variants lost affinity to IL-20R1 and IL-22R1 (shared receptors 1). Back engineering of the variants revealed that reintroduction of a single IL-24 wild-type residue (T198) to the patch interacting with receptors 1 restored 80% of the binding affinity and signaling capacity, accompanied by an acceptable drop in the protein stability by 9 °C. Multiple sequence alignment explains the stabilizing effect of the mutated residues in the IL-24 variants by their presence in the related and more stable cytokines IL-20 and IL-19. Our homology-based approach can enhance existing methods for protein engineering and represents a viable alternative to study and produce difficult proteins for which only in silico structural information is available, estimated as >40% of all important drug targets.
白细胞介素 24(IL-24)是一种细胞因子,具有成为治疗自身免疫性疾病和癌症的有效药物的潜力。然而,其不稳定性和生产困难阻碍了对其进行详细的生物学和生物物理学研究。我们使用 PROSS 算法来设计更稳定的 IL-24 变体,从而解决了 IL-24 生产的挑战。我们使用基于 IL-20 和 IL-19 序列和已知结构构建的同源模型,预测并产生了几个经过广泛突变的 IL-24 变体,这些变体非常稳定且产量很高;其中一个变体(IL-24B,PDB ID 6GG1;3D Interactive 网址:http://proteopedia.org/w/Journal:FEBS_Journal:1)已结晶。然而,突变变体失去了与同源受体细胞外部分的大部分结合能力。虽然与受体 2(IL-20R2)的亲和力得以保留,但变体失去了与 IL-20R1 和 IL-22R1(共享受体 1)的亲和力。变体的反向工程表明,将单个 IL-24 野生型残基(T198)重新引入与受体 1 相互作用的斑块中,可恢复 80%的结合亲和力和信号转导能力,同时蛋白稳定性可接受地降低 9°C。多重序列比对通过存在于相关且更稳定的细胞因子 IL-20 和 IL-19 中,解释了突变残基在 IL-24 变体中的稳定作用。我们基于同源性的方法可以增强现有的蛋白质工程方法,代表了一种可行的替代方案,用于研究和生产只有结构信息的困难蛋白,据估计,这占所有重要药物靶点的>40%。